KR102305089B1 - Manufacturing process of body fluid extract of sea squirt - Google Patents
Manufacturing process of body fluid extract of sea squirt Download PDFInfo
- Publication number
- KR102305089B1 KR102305089B1 KR1020190173933A KR20190173933A KR102305089B1 KR 102305089 B1 KR102305089 B1 KR 102305089B1 KR 1020190173933 A KR1020190173933 A KR 1020190173933A KR 20190173933 A KR20190173933 A KR 20190173933A KR 102305089 B1 KR102305089 B1 KR 102305089B1
- Authority
- KR
- South Korea
- Prior art keywords
- body fluid
- concentration
- sea squirt
- sea
- fluid extract
- Prior art date
Links
- 210000001124 body fluid Anatomy 0.000 title claims abstract description 66
- 241000251555 Tunicata Species 0.000 title claims abstract description 52
- 239000010839 body fluid Substances 0.000 title claims abstract description 51
- 239000000284 extract Substances 0.000 title claims abstract description 46
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000007788 liquid Substances 0.000 claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 239000002244 precipitate Substances 0.000 claims abstract description 18
- 238000000926 separation method Methods 0.000 claims abstract description 6
- 238000005406 washing Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000005909 Kieselgur Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 241000257465 Echinoidea Species 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 18
- 101710104378 Putative malate oxidoreductase [NAD] Proteins 0.000 abstract description 13
- 210000000577 adipose tissue Anatomy 0.000 abstract description 12
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- 208000008589 Obesity Diseases 0.000 abstract description 6
- 235000020824 obesity Nutrition 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 5
- 229910052720 vanadium Inorganic materials 0.000 description 28
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 28
- VLOPEOIIELCUML-UHFFFAOYSA-L vanadium(2+);sulfate Chemical compound [V+2].[O-]S([O-])(=O)=O VLOPEOIIELCUML-UHFFFAOYSA-L 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 19
- 241000700159 Rattus Species 0.000 description 11
- 235000021588 free fatty acids Nutrition 0.000 description 10
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 9
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 230000037396 body weight Effects 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 238000013116 obese mouse model Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 241001474374 Blennius Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 230000003579 anti-obesity Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000004136 fatty acid synthesis Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- -1 vanadyl ion Chemical class 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 238000001636 atomic emission spectroscopy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000011684 zucker rat (obese) Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LTYOQGRJFJAKNA-KKIMTKSISA-N Malonyl CoA Natural products S(C(=O)CC(=O)O)CCNC(=O)CCNC(=O)[C@@H](O)C(CO[P@](=O)(O[P@](=O)(OC[C@H]1[C@@H](OP(=O)(O)O)[C@@H](O)[C@@H](n2c3ncnc(N)c3nc2)O1)O)O)(C)C LTYOQGRJFJAKNA-KKIMTKSISA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- LTYOQGRJFJAKNA-DVVLENMVSA-N malonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-DVVLENMVSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000120 microwave digestion Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000011683 zucker rat (lean) Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/40—Shell-fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
- A23L5/23—Removal of unwanted matter, e.g. deodorisation or detoxification by extraction with solvents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D25/00—Filters formed by clamping together several filtering elements or parts of such elements
- B01D25/12—Filter presses, i.e. of the plate or plate and frame type
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/31—Mechanical treatment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 생체 내에서 말산효소(malic enzyme)의 활성을 저해함으로써 체지방의 합성을 억제하며 비만을 예방 및 개선하는 효능을 갖는 멍게체액 추출물의 제조방법에 관한 것으로, 좀더 상세하게 설명하면, 멍게체액을 고액분리하여 액상성분만 수득하는 단계와, 상기 액상성분에다 에탄올을 첨가하여 단백질이 응집된 침전물을 형성하는 단계와, 상기 침전물을 분리 및 세척하는 단계를 포함하는 멍게체액 추출물의 제조방법에 관한 것이다. The present invention relates to a method for producing a sea squirt bodily fluid extract having the effect of inhibiting the synthesis of body fat and preventing and improving obesity by inhibiting the activity of malic enzyme in vivo. A method for producing a sea urchin body fluid extract comprising the steps of obtaining only a liquid component by solid-liquid separation, adding ethanol to the liquid component to form a precipitate in which proteins are aggregated, and separating and washing the precipitate will be.
Description
본 발명은 생체 내에서 말산효소(malic enzyme)의 활성을 저해함으로써 체지방의 합성을 억제하며 비만을 예방 및 개선하는 효능을 갖는 멍게체액 추출물의 제조방법에 관한 것으로, 좀더 상세하게 설명하면, 멍게체액을 고액분리하여 액상성분만 수득하는 단계와, 상기 액상성분에다 에탄올을 첨가하여 단백질이 응집된 침전물을 형성하는 단계와, 상기 침전물을 분리 및 세척하는 단계를 포함하는 멍게체액 추출물의 제조방법에 관한 것이다. The present invention relates to a method for producing a sea squirt bodily fluid extract having the effect of inhibiting the synthesis of body fat and preventing and improving obesity by inhibiting the activity of malic enzyme in vivo. A method for producing a sea urchin body fluid extract comprising the steps of obtaining only a liquid component by solid-liquid separation, adding ethanol to the liquid component to form a precipitate in which proteins are aggregated, and separating and washing the precipitate will be.
멍게류는 척삭동물군 해초강 측성 해초목에 속하는 생물체로서, 전세계 해양에서 자생하며, 독특한 향이 있고 식용감이 좋아서 식품으로 널리 사용되고 있는 수산물이다. 국내에서는 남해와 동해에서 양식을 통하여 대량 생산이 이루어지고 있다. 그러나 멍게는 내부의 육질만 식용으로 사용되고, 육질 생산 때 발생하는 체액과 껍질 및 내장은 대부분 폐기되고 있다. Sea urchins are creatures that belong to the chordoptera group, seaweeds, and are widely used as food because they are native to the oceans around the world and have a unique flavor and good edible taste. In Korea, mass production is carried out through aquaculture in the South Sea and East Sea. However, only the inner flesh of sea squirts is used for food, and most of the body fluids, skins and intestines generated during meat production are discarded.
이러한 멍게는 특이하게도 체내에 중금속, 특히 바나듐(vanadium)을 축적하여 보호하는 특성이 있다. 멍게에서 바나듐이 결핍되면, 성장 및 생식장애, 신장, 심장 및 뇌의 대사 및 기능 장애가 일어나는 것으로 알려져 있다. 바나듐은 염(vanadate) 및 이온(vanadyl ion) 상태로 멍게체액에 존재하며, 바나딜 이온(vanadyl ion)은 트랜스페린(transferrin)이나 알부민(albumin) 단백질과 결합하여 조직 내에 축적된다. These sea squirts have the characteristic of accumulating and protecting heavy metals, especially vanadium, in the body. Vanadium deficiency in sea squirts is known to cause growth and reproductive disorders, and metabolic and functional disorders of the kidneys, heart and brain. Vanadium is present in seaweed body fluid in the form of a salt (vanadate) and an ion (vanadyl ion), and vanadyl ion (vanadyl ion) binds to transferrin (transferrin) or albumin (albumin) protein and accumulates in the tissue.
한편, 바나듐은 사람 및 포유동물의 필수 영양소로서, 인체 내에서 항당뇨, 항비만, 항고혈압, 항지방 과잉혈증 등의 효능이 있는 것으로 알려져 있다. 그래서 종래에도 멍게로부터 인체에 유용한 바나듐이 함유되어 있는 기능성 물질을 확보하려는 노력들이 시도되어 왔다.On the other hand, as an essential nutrient for humans and mammals, vanadium is known to have anti-diabetic, anti-obesity, anti-hypertension, anti-hyperlipidemia, and the like effects in the human body. Therefore, even in the prior art, efforts have been made to secure a functional material containing vanadium useful for the human body from sea squirt.
예를 들면, 국내 특허 제10-1998301호(2019년 07월 03일)에는, 멍게의 혈장 또는 내장에서 분리된 바나듐 결합 단백질을 포함하는 조성물이 항산화 및 항당뇨 활성을 갖는 기능성 식품으로 사용될 수 있다고 보고되어 있고, 국내 특허 제10-2002962호(2019년 07월 17일)에는 상기 바나듐 결합 단백질을 포함하는 조성물이 비만 예방 및 치료 효능이 있는 기능성 식품으로 사용될 수 있다고 보고되어 있다. For example, in Korean Patent No. 10-1998301 (July 03, 2019), a composition containing vanadium-binding protein isolated from the plasma or intestines of sea squirt can be used as a functional food having antioxidant and antidiabetic activity. It has been reported, and in Korean Patent No. 10-2002962 (July 17, 2019), it is reported that a composition containing the vanadium-binding protein can be used as a functional food having anti-obesity and therapeutic effects.
이상 살핀 바와 같이, 종래에도 멍게 체내에 존재하는 바나듐이 인체 내에서 항당뇨 및 항비만 효능이 있다는 사실은 보고되어 있다. 그리고, 상기 특허 제10-1998301호 및 특허 제10-2002962호의 실시예에는, DEAE-세파로스 이온교환수지 및 세파크릴(Sephacryl) S-200 HR 겔여과 방법을 이용한 크로마토그래피를 사용하여 멍게체액과 내장으로부터 정제된 바나듐 결합 단백질을 추출 및 정제하는 방법이 기재되어 있다. As described above, it has been reported that vanadium present in the body of sea squirts has anti-diabetic and anti-obesity effects in the human body. And, in the Examples of Patent Nos. 10-1998301 and 10-2002962, sea squirt body fluid and A method for extracting and purifying purified vanadium binding protein from the intestine is described.
그러나 상기 실시예에 기재된 방법은 바나듐 결합 단백질의 효능을 시험하기 위하여 실험실 규모에서 실시한 방법으로서, 고가의 이온교환수지를 사용해야 하고 이를 운영하기 위하여 특수한 정제설비가 필요하기 때문에 이러한 방법으로서는 산업적으로 가격 경쟁력이 있는 바나듐 추출물을 제조할 수가 없다. 따라서 지금까지 멍게체액에서 바나듐 함유 추출물을 산업적 규모로 대량생산해 낼 수 있는 방법은 아직 개발되어 있지 않다.However, the method described in the above example is a method carried out on a laboratory scale to test the efficacy of the vanadium-binding protein, and since it requires the use of an expensive ion exchange resin and special purification equipment to operate it, this method is industrially price competitive. It is not possible to prepare a vanadium extract with Therefore, a method for mass production of vanadium-containing extracts from sea squirt body fluid on an industrial scale has not yet been developed.
이에 본 발명의 목적은 멍게체액으로부터 인체에 유용한 바나듐이 다량 함유되어 있는 멍게체액 추출물을 저렴한 비용으로 대량생산해 낼 수 있는 새로운 제조방법을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a new manufacturing method capable of mass-producing sea squirt bodily fluid extract containing a large amount of vanadium useful for the human body from sea squirt fluid at low cost.
본 발명에 따른 멍게체액 추출물의 제조방법은, A) 멍게체액을 2~8℃의 온도에서 고액 분리하여 액상성분만을 수득하는 단계와; B) 상기 액상성분에다 에탄올의 농도가 70~80%로 되도록 고농도 에탄올을 첨가하고, 2~8℃의 온도에서 16~20시간 방치하여 침전물을 형성하는 단계와; C) 상기 침전물을 원심 분리하여 습체를 얻고, 상기 습체를 농도가 80~90%인 에탄올로 세척 한 후 분리 및 건조하는 단계; 를 포함하여 제조되는 것을 특징으로 한다.According to the present invention, a method for producing a sea squirt bodily fluid extract comprises the steps of: A) separating the sea squirt bodily fluid from solid and liquid at a temperature of 2 to 8° C. to obtain only liquid components; B) forming a precipitate by adding high-concentration ethanol to the liquid component so that the concentration of ethanol becomes 70-80%, and leaving it at a temperature of 2-8° C. for 16-20 hours; C) centrifuging the precipitate to obtain a wet body, washing the wet body with ethanol having a concentration of 80 to 90%, separating and drying the wet body; It is characterized in that it is manufactured including.
상기 A) 단계에서는, 상기 멍게체액을 2~8℃의 온도에서 원심 분리하여 상등액을 취하거나, 또는 상기 멍게체액을 2~8℃의 온도에서 규조토가 코팅된 필터프레스(filter press)로 가압 여과하여 여과액을 취하는 방법으로 고액 분리하는 것을 특징으로 한다.In step A), the sea squirt body fluid is centrifuged at a temperature of 2 to 8° C. to obtain a supernatant, or the sea squirt body fluid is filtered under pressure with a filter press coated with diatomaceous earth at a temperature of 2 to 8° C. It is characterized in that the solid-liquid separation is performed by taking the filtrate.
또한 본 발명에 따라 제조되는 멍게체액 추출물은, 바나듐의 농도가 10~25ppm이고, 생체 내에서 말산효소(malic enzyme)의 활성을 저해함으로써 체지방의 합성을 억제하며 비만을 예방 및 개선하는 효능을 갖는 것을 특징으로 한다. In addition, the sea squirt body fluid extract prepared according to the present invention has a vanadium concentration of 10 to 25 ppm and inhibits the synthesis of body fat by inhibiting the activity of malic enzyme in vivo, and has the effect of preventing and improving obesity. characterized in that
본 발명에 따른 멍게체액 추출물의 제조방법은, 대량생산이 가능하고 가격 경쟁력이 높아서 인체에 유용한 바나듐이 다량 함유되어 있는 멍게체액 추출물을 산업적으로 이용 가능한 규모로 생산해 낼 수 있는 효과가 있다.The method for producing a sea squirt bodily fluid extract according to the present invention has the effect of producing an industrially usable sea urchin bodily fluid extract containing a large amount of vanadium useful for the human body because it can be mass-produced and has high price competitiveness.
또한 본 발명에 따라 제조되는 멍게체액 추출물은, 생체 내에서 말산효소(malic enzyme)의 활성을 저해함으로써 체지방의 합성을 억제하며 비만을 예방 및 개선하는 효능이 있어서 기능성 식품 소재로 유용하게 사용될 수 있을 것으로 기대된다.In addition, the sea urchin body fluid extract prepared according to the present invention inhibits the synthesis of body fat by inhibiting the activity of malic enzyme in vivo, and has the effect of preventing and improving obesity, so it can be usefully used as a functional food material. is expected to
도 1은 본 발명의 멍게체액 추출물을 투여한 비만쥐에서 말산효소(malic enzyme)의 혈중 농도변화를 황산바나듐을 투여한 대조군과 비교하여 나타낸 그래프,
도 2는 본 발명의 멍게체액 추출물을 투여한 비만쥐에서 체지방 감소에 대한 기능성 바이오 마커인 NEFA(Non-esterified fatty acid, Free fatty acid)의 농도변화를 황산바나듐을 투여한 대조군과 비교하여 나타낸 그래프,
도 3은 본 발명의 멍게체액 추출물을 투여한 비만쥐에서 체지방 감소에 대한 기능성 바이오 마커인 Tg(Triglyceride)의 농도변화를 황산바나듐을 투여한 대조군과 비교하여 나타낸 그래프,
도 4는 본 발명의 멍게체액 추출물을 투여한 비만쥐와 정상쥐의 체중 변화를 황산바나듐을 투여한 대조군과 비교하여 나타낸 그래프이다.1 is a graph showing the change in blood concentration of malic enzyme in obese rats administered with a sea urchin body fluid extract of the present invention compared to a control group administered with vanadium sulfate;
2 is a graph showing the change in the concentration of NEFA (Non-esterified fatty acid, free fatty acid), which is a functional biomarker for body fat reduction, in obese mice administered with the sea urchin body fluid extract of the present invention compared with the control group administered with vanadium sulfate; ,
3 is a graph showing the change in the concentration of Tg (Triglyceride), a functional biomarker for body fat reduction, in obese mice administered with the sea urchin body fluid extract of the present invention compared with the control group administered with vanadium sulfate;
4 is a graph showing the change in body weight of obese and normal mice administered with a sea urchin bodily fluid extract of the present invention compared with a control group administered with vanadium sulfate.
이하, 첨부한 도면을 이용하여 본 발명을 상세하게 설명한다. 다만, 본 발명을 실시하는데 꼭 필요한 구성이라 하더라도 종래기술에 소개되어 있거나, 통상의 기술자가 공지기술로부터 용이하게 실시할 수 있는 사항에 대해서는 구체적인 설명을 생략한다.Hereinafter, the present invention will be described in detail with reference to the accompanying drawings. However, even if it is a necessary configuration for carrying out the present invention, a detailed description of the matters introduced in the prior art or can be easily implemented by those skilled in the art from the known technology will be omitted.
본 발명에 따른 멍게체액 추출물의 제조방법은, A) 액상성분 수거단계와 B) 침전물 형성단계 및, C) 침전물 건조단계를 포함한다.The method for producing a sea urchin bodily fluid extract according to the present invention includes A) a step of collecting liquid components, B) a step of forming a precipitate, and C) a step of drying the precipitate.
먼저 A) 단계에서는 멍게의 육질을 분리하는 과정에서 발생하는 신선한 멍게체액을 별도로 수거하고, 상기 멍게체액을 2~8℃의 온도에서 고액분리 한 다음, 고형성분을 제거하고 액상성분만을 수득한다. First, in step A), fresh sea squirt body fluid generated in the process of separating the flesh of sea squirt is separately collected, the sea squirt body fluid is separated into solid and liquid at a temperature of 2 to 8 ° C. Then, the solid component is removed and only the liquid component is obtained.
이때 상기 멍게체액을 고액분리하는 방법으로는 예컨대, 상기 멍게체액을 원심 분리하여 상등액을 취하는 방법을 사용할 수도 있고, 상기 멍게체액을 규조토가 코팅된 필터프레스(filter press)로 가압 여과하여 여과액을 취하는 방법을 사용할 수도 있다. 상기 멍게체액을 고액 분리하는 작업은 멍게체액 내에 존재하는 단백질과 활성성분의 변형을 방지하기 위하여 2~8℃의 저온 조건에서 실시하는 것이 바람직하다. At this time, as a method of separating the sea squirt body fluid from solid and liquid, for example, a method of centrifuging the sea squirt body fluid to obtain a supernatant may be used. You can also use the method you take. The solid-liquid separation of the sea squirt body fluid is preferably performed at a low temperature of 2 to 8° C. in order to prevent the transformation of proteins and active ingredients present in the sea squirt body fluid.
또한 상기 멍게체액을 여과하는 필터에 코팅된 규조토(硅藻土)는, 주로 규산(SiO2)으로 이루어지고, 백색 또는 회백색을 띠는 다공질(多孔質) 흙으로서, 멍게체액에 존재하는 불순물이나 색소 및 특이취를 제거하는 기능이 있다. In addition, the diatomaceous earth coated on the filter for filtering the sea squirt body fluid is mainly composed of silicic acid (SiO 2 ) and is white or grayish-white porous soil. It has the function of removing pigments and peculiar odors.
참고로 상기 멍게체액의 양이 100리터 이상 대량인 경우에는 대용량의 원심분리방법을 사용하는 것이 바람직하고, 상기 멍게체액의 양이 비교적 소량인 경우에는 상대적으로 저렴한 비용으로 운용할 할 수 있는 가압 여과방법을 사용하는 것이 바람직하다.For reference, it is preferable to use a large-capacity centrifugal separation method when the amount of sea squirt body fluid is greater than 100 liters, and when the amount of sea squirt body fluid is relatively small, pressure filtration can be operated at a relatively low cost. It is preferable to use the method.
다음으로 B) 단계에서는 상기 A) 단계에서 얻어진 액상성분에다 고농도 에탄올을 첨가하되, 에탄올의 농도를 확인해 가면서 조금씩 첨가한다. 그리고 에탄올의 농도가 70~80%에 이르면 이 상태에서 2~8℃의 온도로 16~20시간 방치한다. 이렇게 하면, 염석(salting out) 현상에 의해서 상기 액성성분 내에 포함되어 있는 유효 단백질이 응집하여 침전물이 생성된다. Next, in step B), high-concentration ethanol is added to the liquid component obtained in step A), and is added little by little while checking the concentration of ethanol. And when the concentration of ethanol reaches 70-80%, it is left in this state at a temperature of 2-8 ℃ for 16-20 hours. In this way, due to the salting out phenomenon, the effective protein contained in the liquid component aggregates to form a precipitate.
일반적으로 염(salt) 또는 에탄올의 농도는 단백질의 용해도에 직접적인 영향을 미친다. 염이나 에탄올의 농도가 낮아지면, 단백질의 용해도가 증가한다. 이온의 세기가 낮은 수용액에서는 단백질 분자가 이온들에 의해 둘러싸여서 단백질의 화학적 활성(chemical activity)이 감소된다. 이렇게 되면 단백질 분자간의 전기적 결합(electrostatic interaction)이 감소하여 용해도가 증가하게 된다. 이러한 상태를 염해(salting in)라고 한다. In general, the concentration of salt or ethanol directly affects the solubility of the protein. When the concentration of salt or ethanol is lowered, the solubility of the protein increases. In an aqueous solution with low ionic strength, the protein molecules are surrounded by ions, and the chemical activity of the protein is reduced. In this way, the electrostatic interaction between the protein molecules is reduced, thereby increasing the solubility. This condition is called salting in.
이러한 염해(salting in) 효과는 단백질에 존재하는 이온들의 해리현상 때문에 발생하지만, 이온의 농도가 훨씬 더 증가하게 되면 단백질의 용해도는 오히려 감소하게 된다. 그래서 다량의 염이나 에탄올 가하여 이온의 농도가 높아지면, 단백질은 용액으로 부터 거의 완전히 해리되어 침전이 발생하게 되는데, 이러한 현상을 염석(salting out)이라고 한다.This salting-in effect occurs due to the dissociation of ions present in the protein, but when the concentration of ions is increased even more, the solubility of the protein is rather decreased. Therefore, when a large amount of salt or ethanol is added to increase the concentration of ions, the protein is almost completely dissociated from the solution and precipitation occurs. This phenomenon is called salting out.
즉, 이온의 농도가 증가하게 되면, 이러한 이온들이 단백질 표면의 소수성 부분에 분포하고 있는 물 분자를 끌어 당기게 되고. 이렇게 되면 단백질 표면의 소수성 부분이 밖으로 노출됨으로써, 단백질 간의 소수성 결합(hydrophobic force)에 의해 침전이 발생하게 되는 것이다. That is, when the concentration of ions increases, these ions attract water molecules distributed in the hydrophobic portion of the protein surface. In this case, the hydrophobic portion of the protein surface is exposed to the outside, and precipitation occurs due to hydrophobic force between proteins.
본 발명의 바람직한 실시예에 따르면, 상기 B) 단계의 고농도 에탄올로는 농도가 95%인 주정(酒精)을 사용하고, 상기 액상성분에 대하여 부피비로 2~4배량의 주정을 첨가하여 에탄올의 농도를 70~80%로 맞추는 것이 바람직하다. According to a preferred embodiment of the present invention, alcohol having a concentration of 95% is used as the high-concentration ethanol in step B), and 2 to 4 times the volume of alcohol is added to the liquid component in a volume ratio to increase the concentration of ethanol It is preferable to set it to 70-80%.
상기 B) 단계에서, 상기 에탄올의 농도가 70% 미만이면, 유호 단백질 성분 중에서 침전이 쉽게 일어나는 일부 단백질만 침전되고, 그 나머지 많은 유효 단백질들은 침전이 일어나지 않는 문제가 있다. 반대로 상기 에탄올의 농도가 80%를 초과하면, 모든 단백질이 침전 되면서 불순물이 많이 발생하는 문제가 있다. In step B), if the concentration of the ethanol is less than 70%, only some proteins that easily precipitate among the milk protein components are precipitated, and there is a problem that the remaining many effective proteins do not precipitate. Conversely, when the concentration of ethanol exceeds 80%, there is a problem in that a lot of impurities are generated while all proteins are precipitated.
또한 상기 B) 단계의 작업 온도가 2℃ 미만이면, 너무 저온이라 작업이 곤란한 문제가 있고, 반대로 8℃를 초과하면 단백질 성분이 변성을 일으킬 우려가 있어서 바람직하지 않다. In addition, if the working temperature of step B) is less than 2° C., there is a problem that the operation is difficult because it is too low. On the contrary, if it exceeds 8° C., it is not preferable because there is a possibility that the protein component may be denatured.
마지막 C) 단계에서는 상기 침전물을 원심 분리하여 습체를 얻고, 상기 습체를 농도가 80~90%인 에탄올로 세척 한 후 분리 및 건조하면, 본 발명의 멍게체액 추출물이 수득된다.In the last step C), the precipitate is centrifuged to obtain a wet body, and the wet body is washed with ethanol having a concentration of 80 to 90%, separated and dried to obtain the sea urchin body fluid extract of the present invention.
여기서 상기 에탄올의 농도가 80% 미만이면 습체에 포함되어 있는 유효 단백질이 용해되어 수율이 감소할 우려가 있고, 반대로 90%를 초과하면 농도 증가에 따른 상승효과는 거의 없으면서 주정의 사용량이 증가하여 제조원가만 상승하기 때문에 바람직하지 않다.Here, if the concentration of ethanol is less than 80%, the effective protein contained in the wet body is dissolved and there is a fear that the yield may decrease. It is undesirable because it only rises.
상기와 같은 방법으로 제조되는 멍게체액 추출물은 분말 형태로 수득되며, 바나듐의 농도가 10~25ppm인 것으로 확인되었다. 또한, 상기 멍게체액 추출물은 생체내에서 말산효소(malic enzyme)의 활성을 저해함으로써 결과적으로 체지방의 합성을 억제하고, 비만을 예방 및 개선하는 효능이 있는 것으로 확인되었다.The sea urchin body fluid extract prepared by the above method was obtained in powder form, and it was confirmed that the concentration of vanadium was 10 to 25 ppm. In addition, it was confirmed that the sea squirt body fluid extract inhibits the activity of malic enzyme in vivo, thereby inhibiting the synthesis of body fat, and preventing and improving obesity.
이하, 바람직한 실시예에 따라서 본 발명을 상세히 설명한다. 단, 하기 실시예는 본 발명을 보다 구체적으로 예시하는 것이므로, 이들 실시예에 의해서 본 발명의 보호 범위가 제한되는 것은 아니다.Hereinafter, the present invention will be described in detail according to preferred embodiments. However, since the following examples illustrate the present invention in more detail, the protection scope of the present invention is not limited by these examples.
신선한 멍게체액을 수거하고 상기 멍게체액을 원심 분리하여 고형성분이 제거된 상등액 30리터를 수득하였다. 상기 상등액에다 95% 주정 90리터를 적가하면서 서서히 교반하여 에탄올의 농도를 75%로 조정하고, 4℃에서 16~20시간 방치하하여 침전물이 생성된 것을 확인하였다.Fresh sea squirt body fluid was collected and centrifuged to obtain 30 liters of a supernatant from which solids were removed. To the supernatant, 90 liters of 95% alcohol was added dropwise while stirring slowly to adjust the ethanol concentration to 75%, and it was left at 4° C. for 16 to 20 hours to confirm that a precipitate was formed.
이어 상기 침전물을 원심분리(8xg, 20min, 4℃) 하여 습체 872g을 수득하였다. 상기 습체를 4℃의 온도에서 80% 에탄올 300ml으로 30분간 세척하고, 다시 원심분리(8xg, 20min, 4℃) 하여 불순물이 제거된 습체 781g을 수득하였다. 상기 습체를 50℃의 온도에서 5시간 진공 건조하여 분말 상태의 멍게체액 추출물 285g을 수득하였다.Then, the precipitate was centrifuged (8xg, 20min, 4°C) to obtain 872 g of a wet body. The wet body was washed with 300 ml of 80% ethanol at a temperature of 4° C. for 30 minutes, and centrifuged again (8×g, 20 min, 4° C.) to obtain 781 g of a wet body from which impurities were removed. The wet body was vacuum-dried at a temperature of 50° C. for 5 hours to obtain 285 g of a powdery sea urchin body fluid extract.
신선한 멍게체액을 규조토로 코팅된 필터프레스(Filter press)로 여과하여 고형분이 제거된 여과액 30리터를 수득하였다. 상기 상등액에다 주정(95%) 90리터를 적가하면서 서서히 교반하여 에탄올의 농도를 75%로 조정하고, 4℃에서 18시간 방치하여 침전물이 생성된 것을 확인하였다.The fresh sea urchin body fluid was filtered through a filter press coated with diatomaceous earth to obtain 30 liters of a filtrate from which solids were removed. To the supernatant, 90 liters of alcohol (95%) was added dropwise while stirring slowly to adjust the concentration of ethanol to 75%, and it was confirmed that a precipitate was formed by allowing it to stand at 4°C for 18 hours.
이어 상기 침전물을 원심분리(8xg, 20min, 4℃) 하여 습체 912g을 수득하였다. 상기 습체를 4℃의 온도에서 80% 에탄올 300ml으로 30분간 세척하고, 다시 원심분리(8xg, 20min, 4℃) 하여 불순물이 제거된 습체 826g을 수득하였다. 상기 습체를 50℃의 온도에서 5시간 진공 건조하여 분말 상태의 멍게체액 추출물 331g을 수득하였다.Then, the precipitate was centrifuged (8xg, 20min, 4°C) to obtain 912 g of a wet body. The wet body was washed with 300 ml of 80% ethanol at a temperature of 4° C. for 30 minutes, and centrifuged again (8×g, 20 min, 4° C.) to obtain 826 g of a wet body from which impurities were removed. The wet body was vacuum-dried at a temperature of 50° C. for 5 hours to obtain 331 g of a powdery seaweed extract.
[시험예][Test Example]
1) 바나듐의 함량 측정1) Determination of vanadium content
ICP-OES(Inductively Coupled Plasm Optical Emission Spectrometry, Perkin Elmer/ OES-8300)를 이용하여 상기 실시예 1,2에 따라 수득된 멍게체액 추출물에 포함되어 있는 바나듐의 함량을 분석 및 측정하였다. 상기 멍게체액 추출물에서 각각 일정량(0.1~0.5g)의 시료를 채취하여 Microwave digestion system(Mars/ Mars 5)에 넣고, 질산(HNO3) 7mL과 과산화수소 1mL을 첨가한 후, Digestion program(5min, 80°C, 1000W → 5min, 50°C, 1000W → 15min, 190°C, 1000W → 20min, 190°C, 1000W)으로 처리하여 분해하였다. The content of vanadium contained in the sea urchin bodily fluid extract obtained according to Examples 1 and 2 was analyzed and measured using ICP-OES (Inductively Coupled Plasm Optical Emission Spectrometry, Perkin Elmer/OES-8300). A certain amount (0.1~0.5g) of each sample is collected from the sea squirt body fluid extract, put into a microwave digestion system (Mars/ Mars 5), nitric acid (HNO 3 ) 7mL and hydrogen peroxide 1mL are added, and the Digestion program (5min, 80 °C, 1000W → 5min, 50°C, 1000W → 15min, 190°C, 1000W → 20min, 190°C, 1000W).
분해가 완료 된 시료를 식혀서 매스 플라스크에 일정량을 취한 다음, ICP-OES(Inductively Coupled Plasm Optical Emission Spectrometry, Perkin Elmer/ OES-8300)를 이용하여 바나듐 원소를 유도결합 플라즈마에 의해 이온화하고, 이온화된 원소의 질량/전하수의 비(m/z)에 따라 분리된 이온 스펙트라와 그 강도를 분석하였다. After cooling the decomposed sample, a certain amount is taken into the mass flask, and then the vanadium element is ionized by inductively coupled plasma using ICP-OES (Inductively Coupled Plasm Optical Emission Spectrometry, Perkin Elmer/OES-8300), and the ionized element The separated ion spectra and its intensity were analyzed according to the mass/charge ratio (m/z) of
바나듐 표준품을 각각 5, 1, 0.5, 0.1 mg/L의 농도로 준비하여 검량선용 표준용액(Quality control standard 21/Perkin Elmer/99%)을 제조하였다. 상기 검량선용 표준용액을 ICP-MS로 분석하고, 피크 데이터를 플롯(plot)하여 정량분석을 위한 표준 검량선을 작성하였다. 상기 표준 검량선에 대해 확산된 농도값을 얻고, 희석배율(50~100)을 곱하여 상기 시료들에 대한 바나듐의 함량(g) 및 농도(ppm)를 산출한 다음, 그 결과를 다음 표 1에 수록하였다. Vanadium standards were prepared at concentrations of 5, 1, 0.5, and 0.1 mg/L, respectively, to prepare standard solutions for calibration curves (Quality control standard 21/Perkin Elmer/99%). The standard solution for the calibration curve was analyzed by ICP-MS, and the peak data was plotted to prepare a standard calibration curve for quantitative analysis. The concentration value diffused with respect to the standard calibration curve is obtained, and the content (g) and concentration (ppm) of vanadium for the samples are calculated by multiplying the dilution factor (50 to 100), and then the results are listed in Table 1 did.
획득수율of vanadium
Acquisition yield
상기 [ 표 1 ]에서, ‘바나듐의 획득수율(%)’은 ‘멍게체액 추출물의 바나듐 함량(mg)’을 ‘멍게체액의 바나듐 함량(mg)’으로 나눈 값을 백분율(%)로 나타낸 것이다. 그리고 실시예 1에서 사용한 멍게체액과 실시예 2에서 사용한 멍게체액의 바나듐 농도가 서로 다른 이유는, 상기 실시예 1 및 실시예 2에서 서로 다른 계절에 수확한 멍게의 체액을 사용하였기 때문인 것으로 추측된다. In [Table 1], the 'vanadium yield (%)' is the value obtained by dividing the 'vanadium content (mg) of the sea squirt body fluid extract' by the 'vanadium content (mg) of the sea squirt bodily fluid (mg)' is expressed as a percentage (%). . And the reason that the vanadium concentration of the sea squirt body fluid used in Example 1 and the sea squirt body fluid used in Example 2 is different is presumed to be because the body fluids of sea squirt harvested in different seasons in Examples 1 and 2 were used. .
2) 말산효소(malic enzyme)의 활성저해 효능시험2) Malic enzyme activity inhibition efficacy test
식품의약품안전처에서 발행한 “건강기능식품 기능성 평가 가이드(2012.03)” 의 “체지방 감소의 도움” 편을 참고하면, 말산효소(malic enzyme)가 체지방의 합성과 관여하는 것으로 알려져 있다. 즉, 체지방 합성은 지방산 합성과 중성지방 합성 과정을 거치는데, 이때 지방산 합성은 주로 간의 세포질에서 진행된다. 미토콘드리아에서는 말산효소의 작용으로 포도당으로부터 Acetyl CoA를 생성하고, 상기 Acetyl CoA는 지방산 합성이 일어나는 세포질로 이동하기 위해 옥살로아세트산(oxaloacetate)과 결합하여 구연산염(citrate)을 형성한다. If you refer to the “Help in reducing body fat” section of “Health functional food functional evaluation guide (2012.03)” issued by the Ministry of Food and Drug Safety, it is known that malic enzyme is involved in the synthesis of body fat. That is, body fat synthesis undergoes fatty acid synthesis and triglyceride synthesis, and at this time, fatty acid synthesis mainly proceeds in the cytoplasm of the liver. Acetyl CoA is produced from glucose by the action of malic enzyme in mitochondria, and the Acetyl CoA combines with oxaloacetate to form citrate in order to move to the cytoplasm where fatty acid synthesis occurs.
상기 구연산염은 세포질로 운반된 후 다시 옥살로아세트산과 Acetyl CoA로 분해되고, 상기 Acetyl CoA는 Acetyl CoA carboxylase의 작용에 의하여 Malonyl CoA를 생성한 다음, Fatty acid synthase complex의 작용에 의하여 지방산을 합성한다. 따라서 상기 미토콘드리아에서 작용하는 말산효소의 활성을 저해하면, 지방산의 합성을 억제할 수 있다.After the citrate is transported to the cytoplasm, it is again decomposed into oxaloacetic acid and Acetyl CoA. The Acetyl CoA produces malonyl CoA by the action of Acetyl CoA carboxylase, and then synthesizes fatty acids by the action of the Fatty acid synthase complex. Therefore, when the activity of malic enzyme acting on the mitochondria is inhibited, the synthesis of fatty acids can be inhibited.
이러한 대사기전에 근거하여 본 발명에 따라 제조되는 멍게체액 추출물이 말산효소의 활성에 어떤 영향을 미치는지 확인하기 위하여 다음과 같은 시험을 실시하였다. 상기 실시예 2에서 수득한 멍게체액 추출물 100mg/kg을 비만쥐(obese zucker rats)에게 단회 경구투여 하고, 대조군에 대해서는 황산바나듐(Vanadium sulfate: VS)을 10mg/kg, 30mg/kg, 90mg/kg 씩 단회 경구투여하였다.Based on this metabolic mechanism, the following test was conducted to determine how the sea squirt body fluid extract prepared according to the present invention affects the activity of malic enzyme. 100 mg/kg of the sea urchin body fluid extract obtained in Example 2 was orally administered once to obese zucker rats, and for the control group, 10 mg/kg, 30 mg/kg, and 90 mg/kg of vanadium sulfate (VS) was administered. Each was orally administered once.
투여 후 24시간 및 120시간이 경과한 시점에서 각각 상기 비만쥐의 혈액을 채취하여 혈액 내 말산효소의 농도 변화를 측정하고 그 결과를 첨부 도 1의 그래프에 수록하였다. 첨부 도 1의 그래프에서 푸른색 막대그래프는 24시간 경과 후의 저해효능(%)을 나타낸 것이고, 주황색 막대그래프는 120시간 경과 후의 저해효능(%)을 나타낸 것이다. 또한, ‘멍게추출물’은 본 발명의 멍게체액 추출물 100mg/kg을 투여한 시험군이고, ‘VS 10mg/kg, VS 30mg/kg, VS 90mg/kg’은 각각 황산바나듐 10mg/kg, 30mg/kg 및 90mg/kg을 투여한 대조군이다.At 24 hours and 120 hours after administration, the blood of the obese rats was collected, respectively, and the change in the concentration of malic enzyme in the blood was measured, and the results were recorded in the graph of FIG. 1 attached. In the graph of FIG. 1, the blue bar graph shows the inhibitory effect (%) after 24 hours, and the orange bar graph shows the inhibitory effect (%) after 120 hours. In addition, 'sea squirt extract' is a test group administered with 100 mg/kg of the sea squirt body fluid extract of the present invention, and '
시험 결과, 대조군에서는 황산바나듐(VS)의 투여량이 증가할수록 말산효소에 대한 저해효능이 증가하는 것으로 나타났다. 그리고 황산바나듐(VS)의 투여량이 10mg/kg으로 소량인 경우에는 투여 후 24시간 까지 저해효능이 유지되었으나, 투여량을 30mg/kg 및 90mg/kg으로 증량한 경우에는 상기 저해효능이 120시간까지 유지되는 것으로 나타냈다. As a result of the test, in the control group, it was found that the inhibitory effect on malic enzyme increased as the dose of vanadium sulfate (VS) increased. And when the dose of vanadium sulfate (VS) was small, 10 mg/kg, the inhibitory effect was maintained until 24 hours after administration, but when the dose was increased to 30 mg/kg and 90 mg/kg, the inhibitory effect was maintained up to 120 hours. appeared to be maintained.
그리고 본 발명의 멍게체액 추출물 100mg/kg을 투여한 시험군의 경우에는 상기 대조군에 비해 전체적으로 더 우수한 효능을 나타내었고, 특히 24시간을 경과한 시점보다 120시간을 경과한 시점에서 말산효소에 대한 저해효능이 더 증가하는 것으로 나타났다. In addition, the test group administered with 100 mg/kg of the sea urchin bodily fluid extract of the present invention showed overall better efficacy than the control group, and in particular, the inhibition of malate enzyme at the time of 120 hours rather than the time of 24 hours. It has been shown to further increase the efficacy.
3) 비만예방 효능시험3) Obesity prevention efficacy test
본 발명에 따라 제조된 멍게체액 추출물이 체지방 합성 및 체중의 증가에 어떤 영향을 주는지 확인하기 위하여, 정상쥐(lean zucker rats)와 비만쥐(obese zucker rats)에게 각각 상기 실시예 2의 멍게체액 추출물 100mg/kg을 단회 경구 투여 한 후, 체지방 감소의 기능성 바이오 마커인 NEFA(Non-esterified fatty acid)및 Tg(Triglyceride)의 농도와 쥐의 체중 변화를 5일(120시간) 동안 측정하였다. In order to confirm the effect of the sea urchin bodily fluid extract prepared according to the present invention on body fat synthesis and weight gain, the sea urchin bodily fluid extract of Example 2 was administered to lean zucker rats and obese zucker rats, respectively. After a single oral administration of 100 mg/kg, the concentrations of non-esterified fatty acid (NEFA) and triglyceride (Tg), which are functional biomarkers for reducing body fat, and the change in body weight of mice were measured for 5 days (120 hours).
대조군에게는 황산바나듐(VS) 10mg/kg, 30mg/kg, 90mg/kg을 각각 단회 경구 투여하고, 동일한 방법으로 NEFA와 Tg의 변화 및 체중 변화를 측정하였다. 첨부 도 2는 비만쥐에 대한 NEFA(Non- esterified fatty acid)의 농도변화를 수록한 것이고, 도 3은 비만쥐에 대한 Tg(Triglyceride)의 농도를 수록한 것이다. To the control group, 10 mg/kg, 30 mg/kg, and 90 mg/kg of vanadium sulfate (VS) were orally administered once, respectively, and changes in NEFA and Tg and changes in body weight were measured in the same manner. Attached Figure 2 is to record the concentration change of NEFA (Non-esterified fatty acid) for obese mice, Figure 3 is to record the concentration of Tg (Triglyceride) for obese mice.
첨부 도 2 및 도 3에서 ‘fatty-멍게’는 본 발명의 멍게체액 추출물 100mg/kg을 투여한 비만쥐 시험군이고, ‘fatty-10, fatty-30, fatty-90’은 각각 황산바나듐 10mg/kg, 30mg/kg, 90mg/kg을 투여한 비만쥐 대조군이다. 2 and 3, 'fatty-seaweed' is a test group of obese rats administered 100mg/kg of the sea squirt body fluid extract of the present invention, and 'fatty-10, fatty-30, fatty-90' is vanadium sulfate 10mg/kg, respectively. A control group of obese rats administered with kg, 30 mg/kg, and 90 mg/kg.
시험 결과, 본 발명의 멍게체액 추출물 100mg/kg을 단회 투여한 비만쥐(fatty_멍게)에서 시료 투여 후 12시간 경과시까지 NEFA 및 Tg의 농도가 유의성 있게 감소하였다가 12시간 경과 이후부터는 다시 증가하는 것으로 나타났다. 황산바나듐 10mg/kg 및 30mg/kg을 단회 투여한 대조군(fatty_10/ fatty_30) 의 경우에는 본 발명의 멍게체액 추출물 100mg/kg을 투여한 시험군과 거의 유사한 패턴을 보였으나, 황산바나듐 90mg/kg을 단회 투여한 대조군(fatty_90)은 120시간을 경과할 때 까지 계속 NEFA와 Tg의 농도를 낮게 유지하였다. As a result of the test, the concentrations of NEFA and Tg were significantly decreased until 12 hours after sample administration in obese rats (fatty_sea squirt) administered once 100 mg/kg of the sea squirt body fluid extract of the present invention, and then increased again after 12 hours. appeared to do The control group (fatty_10/fatty_30) administered with 10 mg/kg and 30 mg/kg of vanadium sulfate showed a pattern almost similar to that of the test group administered with 100 mg/kg of the sea urchin bodily fluid extract of the present invention, but 90 mg/kg of vanadium sulfate was administered. The single-administered control group (fatty_90) kept the concentrations of NEFA and Tg low until 120 hours had elapsed.
한편, 도 4는 비만쥐와 정상쥐의 체중변화를 나타낸 그래프로서, ‘fatty-멍게 추출물’은 본 발명의 멍게체액 추출물 100mg/kg을 투여한 비만쥐 시험군이고, ‘lean-멍게 추출물’은 본 발명의 멍게체액 추출물 100mg/kg을 투여한 정상쥐 시험군이다. 그리고, ‘fatty-VS10, fatty-VS30, fatty-VS90’은 각각 황산바나듐 10mg/kg, 30mg/kg, 90mg/kg을 투여한 비만쥐 대조군이고, ‘lean-VS10, lean-VS30, lean-VS90’은 황산바나듐 10mg/kg, 30mg/kg, 90mg/kg을 투여한 정상쥐 대조군이다.On the other hand, Figure 4 is a graph showing the change in body weight of obese and normal rats, 'fatty-sea squirt extract' is a test group of obese rats administered with 100 mg/kg of the sea squirt body fluid extract of the present invention, and 'lean- sea squirt extract' is This is a normal mouse test group administered with 100 mg/kg of the sea urchin body fluid extract of the present invention. And, 'fatty-VS10, fatty-VS30, and fatty-VS90' were control groups of obese rats administered 10 mg/kg, 30 mg/kg, and 90 mg/kg of vanadium sulfate, respectively, and 'lean-VS10, lean-VS30, lean-VS90' ' is a control group of normal rats administered 10 mg/kg, 30 mg/kg, and 90 mg/kg of vanadium sulfate.
첨부 도 4에서 보는 바와 같이, 본 발명의 멍게체액 추출물 100mg/kg을 단회 투여한 경우, 3일차까지 비만쥐(fatty)와 정상쥐(lean) 모두 체중 증가가 아주 낮았지만 4일차 이후 체중이 급격하게 증가하였다. 황산바나듐 10mg/kg, 30mg/kg 및 90mg/kg을 단회 투여한 대조군(VS 10mg/VS 30mg/VS 90mg)에서도 이와 유사하게 쥐의 체중 증가를 억제하는 결과를 나타내었다.As shown in FIG. 4 , when 100 mg/kg of the sea urchin body fluid extract of the present invention was administered once, weight gain was very low in both fatty and lean rats until the 3rd day, but after the 4th day, the body weight rapidly increased. increased. A control group (VS 10mg/VS 30mg/VS 90mg) administered with 10 mg/kg, 30 mg/kg and 90 mg/kg of vanadium sulfate similarly suppressed weight gain in rats.
Claims (5)
B) 상기 액상성분에다 에탄올의 농도가 70~80%로 되도록 고농도 에탄올을 첨가하고, 2~8℃의 온도에서 16~20시간 방치하여 단백질이 응집된 침전물을 형성하는 단계와;
C) 상기 침전물을 원심 분리하여 습체를 얻고, 상기 습체를 농도가 80~90%인 에탄올로 세척 한 후 분리 및 건조하는 단계;
를 포함하여 제조되는 것을 특징으로 하는 멍게체액 추출물의 제조방법.
A) solid-liquid separation of sea squirt body fluid at a temperature of 2 to 8° C. to obtain only liquid components;
B) adding high-concentration ethanol to the liquid component so that the concentration of ethanol is 70-80%, and leaving it at a temperature of 2-8° C. for 16-20 hours to form a precipitate in which proteins are aggregated;
C) centrifuging the precipitate to obtain a wet body, washing the wet body with ethanol having a concentration of 80 to 90%, separating and drying the wet body;
A method for producing a sea squirt body fluid extract, comprising:
The method according to claim 1, wherein in step A), the sea squirt body fluid is centrifuged at a temperature of 2 to 8° C. and the supernatant is separated from solid and liquid.
[Claim 2] The method of claim 1, wherein in step A), the sea squirt body fluid is filtered under pressure using a filter press coated with diatomaceous earth at a temperature of 2 to 8° C. Method for producing sea squirt body fluid extract.
According to claim 1, wherein the high-concentration ethanol in step B) uses alcohol having a concentration of 95%, and 2-4 times the volume ratio of the liquid component is added to increase the concentration of ethanol to 70-80%. A method for producing a sea squirt body fluid extract, characterized in that it is matched.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190173933A KR102305089B1 (en) | 2019-12-24 | 2019-12-24 | Manufacturing process of body fluid extract of sea squirt |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190173933A KR102305089B1 (en) | 2019-12-24 | 2019-12-24 | Manufacturing process of body fluid extract of sea squirt |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210081711A KR20210081711A (en) | 2021-07-02 |
KR102305089B1 true KR102305089B1 (en) | 2021-09-27 |
Family
ID=76897003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190173933A KR102305089B1 (en) | 2019-12-24 | 2019-12-24 | Manufacturing process of body fluid extract of sea squirt |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102305089B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102683369B1 (en) * | 2021-11-02 | 2024-07-10 | 주식회사 케이제이엠바이오 | Method for producing nano exosome derived from aloe bark callus and composition for skin improvement comprising nano exosomes derived from Aloe bark callus prepared accordingly |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101998301B1 (en) | 2018-02-19 | 2019-07-09 | 강릉원주대학교산학협력단 | Vanadium binding proteins purified from the sea squirt and functional food composition comprising this |
KR102002962B1 (en) * | 2018-02-19 | 2019-07-23 | 강릉원주대학교산학협력단 | Composition for anti-obesity using vanadium binding proteins purifiedfrom the sea squirt and functionalfood composition comprising this |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100387162B1 (en) | 2000-06-23 | 2003-06-11 | 오석수 | Method for constructing yellow soil building using C-shape steel |
KR101055392B1 (en) * | 2008-11-04 | 2011-08-08 | 호서대학교 산학협력단 | Composition comprising the extract of halocynthia roretzi which contains antimicrobial peptide for preventing and treating gastrointestinal diseases |
-
2019
- 2019-12-24 KR KR1020190173933A patent/KR102305089B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101998301B1 (en) | 2018-02-19 | 2019-07-09 | 강릉원주대학교산학협력단 | Vanadium binding proteins purified from the sea squirt and functional food composition comprising this |
KR102002962B1 (en) * | 2018-02-19 | 2019-07-23 | 강릉원주대학교산학협력단 | Composition for anti-obesity using vanadium binding proteins purifiedfrom the sea squirt and functionalfood composition comprising this |
Also Published As
Publication number | Publication date |
---|---|
KR20210081711A (en) | 2021-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6440468B1 (en) | Method for obtaining apolar and polar extracts of curcuma and applications thereof | |
AU2021290454B2 (en) | Process for Obtaining a Purified Psychoactive Alkaloid Solution | |
JP2004506657A (en) | Bioavailable compositions of natural and synthetic HCA | |
JP5597136B2 (en) | Method for producing composition containing high sapogenin | |
JPS6137896B2 (en) | ||
WO2021253116A1 (en) | Compositions comprising psychoactive compounds from psychoactive organisms | |
JP2014533676A (en) | Composition comprising chicory extract | |
KR102305089B1 (en) | Manufacturing process of body fluid extract of sea squirt | |
Florin et al. | Protective effects of aqueous extract of Sempervivum tectorum L (Crassulaceae) on aluminium-induced oxidative stress in rat blood | |
WO2011004734A1 (en) | Carboxymethylarginine production inhibitor and collagen denaturation inhibitor | |
KR102309913B1 (en) | Composition for improving hangover cure and alcoholic liver injury comprising root extract of Rosa multiflora THUNB | |
EP0352146B1 (en) | Biological regulator extracted from Gingko Biloba, active in different pathologies. | |
CN101491618A (en) | Method for separating tobacco total alkaloid from extract liquid of tobacco leftovers | |
JP4385243B2 (en) | Composition for preventing or treating inflammation involving type IV allergic reaction | |
CN110128437A (en) | A kind of high-purity ellagic acid and the preparation method and application thereof | |
El-Sheshtawy et al. | Protective Effect of Yucca Schidigera extract against lead induced-toxicity in NewZealand male rabbits | |
KR101320149B1 (en) | Urushiol reduction disposed lacquer, lacquer extract by using the same and Method of manufacturing the same | |
JP2005068112A (en) | Extract from grifola frondosa (a kind of mushroom) and glycoprotein and method for producing the same | |
Venkatachalam et al. | Fabrication of bioactive molecules loaded chitosan nanoparticles using Gymnema sylvestre leaf extracts and its antidiabetic potential in experimental rat model | |
Li et al. | Inhibitory effect of Athelia rolfsii exopolysaccharides on organ damage in lead-exposed Kunming strain mice | |
Lakshmi et al. | Modification of mercury-induced biochemical alterations by Triticum Aestivum Linn in rats | |
US6372265B2 (en) | Anti-oxidant reducing substance and method of producing the same | |
JP3480965B2 (en) | Method for preparing amylase inhibitor | |
CN111138559B (en) | Preparation method of phosphorylated lotus root polysaccharide and antioxidant or antitumor drug | |
JP3308497B2 (en) | SOD-like extract composition extracted from coffee beans |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |